Whitehawk Therapeutics, Inc. (WHWK)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $180.57M
Last updated: Nov 17, 2026 at 11:04 AM ET
Whitehawk Therapeutics, Inc. (WHWK) Stock Forecast
Analysts expect Whitehawk Therapeutics (WHWK) to earn -$0.97 per share in the fiscal year ending Dec 31, 2026. Of 9 analysts, 6 rate the stock Buy or Strong Buy, 3 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 9 ratings average 2.22, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 67% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 11.1% |
| Buy | 5 | 55.6% |
| Hold | 3 | 33.3% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 9
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss.
- Fiscal year ending Dec 31, 2026
- -$0.97
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$1.00
- EPS consensus
- Next report
- Mar 10, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.97 | -$1.02 to -$0.92 | 3 |
| Dec 31, 2027 | -$1.00 | -$1.06 to -$0.90 | 4 |
Quarterly Estimates
The EPS consensus falls from -$0.22 for the quarter ending Dec 31, 2026 to -$0.23 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.22 | -$0.25 to -$0.14 | 11 |
| Mar 31, 2027 | -$0.23 | -$0.24 to -$0.22 | 2 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 6 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 0 |
| Fiscal year ending Dec 31, 2027 | 2 | 0 |
| Quarter ending Mar 31, 2027 | 2 | 0 |
EPS Trend
The EPS consensus for the fiscal year ending Dec 31, 2026 has held over the last 90 days.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.97 | -$0.97 | -$0.97 | -$0.97 | -$0.97 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.00 | -$0.99 | -$0.99 | -$0.99 | -$0.99 | N/A |
| Quarter ending Mar 31, 2027 | -$0.23 | -$0.24 | -$0.24 | -$0.24 | -$0.24 | N/A |
Frequently Asked Questions About WHWK
What is the WHWK stock forecast?
Consensus analyst estimates put Whitehawk Therapeutics's EPS at -$0.97 for the fiscal year ending Dec 31, 2026. The consensus rating from 9 analysts is Buy.
How do analysts rate WHWK stock?
Of 9 analysts covering Whitehawk Therapeutics, 1 rates it Strong Buy, 5 Buy, 3 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from WHWK next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.97, with estimates from -$1.02 to -$0.92 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.00, with estimates from -$1.06 to -$0.90 from 4 analysts.
How many analysts cover WHWK?
9 analysts rate Whitehawk Therapeutics stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
WHWK pages: Overview, Earnings, Forecast, Financials, Competitors